Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

• मुख्य लेखकों: Alexander Egeberg (लेखक), Jason E. Hawkes (लेखक), Najwa Somani (लेखक), Russel Burge (लेखक), Kyoungah See (लेखक), Gaia Gallo (लेखक), Missy McKean-Matthews (लेखक), Melinda Gooderham (लेखक), George Han (लेखक), April Armstrong (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Adis, Springer Healthcare, 2024-04-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat with non-systemic therapies, this post hoc analysis f...